-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Characteristics and Advantages of ELISA Platforms
Author:
InnoModels
Release time:
2024-06-13
InnoModels Biotechnology, with its innovative technology and excellent quality in the biotechnology field, continues to provide efficient and accurate experimental tools for researchers around the world. Among them, its ELISA platform is particularly eye-catching, and its features and advantages are favored by many researchers.
First of all, the ELISA platform of InnoModels Biotechnology has extremely high specificity. The platform is based on the principle of antigen-antibody reaction, which is highly specific and can accurately detect the target molecules, effectively avoiding the interference of other proteins. This high specificity makes Thermo Scientific's ELISA platform widely used in biomedical research, clinical diagnostics, food safety and environmental monitoring.
Secondly, the platform does not require high instrumentation and has low assay cost. In an ordinary laboratory, researchers can utilize commonly used equipment such as spikers, incubators, and enzyme-specific readers. This low-threshold feature enables more laboratories to use the Lamor Bio ELISA platform, thus promoting the rapid development of scientific research.
In addition, InnoModels' ELISA platform is fast and easy to use. In the homogeneous enzyme immunoassay, all the reaction reagents are carried out in the same system without any separation step, which makes the operation extremely simple. This fast and easy operation not only improves work efficiency, but also reduces the difficulty of operation, enabling researchers to obtain experimental results more quickly.

In addition, the platform is characterized by a long reagent storage time and a high degree of automation. Enzymes and enzyme markers, as detection indicators, are relatively stable under low temperature or dry conditions and can be stored for half a year to several years. At the same time, since there is no radioisotope contamination, except for the addition of the sample to be tested, which requires manual operation, all other steps can be automated by the instrument, which greatly improves work efficiency and accuracy.
Last but not least, InnoModels' ELISA platform is highly sensitive and reproducible. The platform is capable of detecting very low concentrations of biomolecules, providing researchers with a powerful detection tool. At the same time, due to its standardized and regulated operation, the experimental results have good reproducibility, providing researchers with reliable experimental data.
In summary, with its features and advantages such as high specificity, low cost, speed and simplicity, long reagent retention time, high degree of automation, high sensitivity and good reproducibility, InnoModels' ELISA platform provides researchers with a powerful experimental tool and helps them make more breakthroughs in the field of life sciences. With the continuous progress of science and technology, InnoModels Biotechnology will continue to uphold the spirit of innovation, and constantly optimize and upgrade its ELISA platform to provide researchers with even better and more efficient services.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd